Concepedia

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

Per Soelberg Sørensen, Nils Koch‐Henriksen, Corinna N. Ross, Katja Maria Clemmesen, Klaus Bendtzen

Neurology · 2005 · 193 citations · 28 references

Abstract

NABs should be measured in all patients treated with IFN-beta. If patients have been persistently NAB-negative for 24 months, measurements can be discontinued. Patients who have been NAB-positive for a period of 18 months or more usually remain NAB-positive for a long time.

References

28

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

Lawrence Jacobs, Diane L. Cookfair, Richard A. Rudick et al. · Annals of Neurology · 1996 · 2.4K citations

Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

Neurology · 1993 · 2.1K citations

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

George C. Ebers · The Lancet · 1998 · 2.1K citations

Interferon β-1A, Double-blind Placebo-controlled Study, Autoimmune Disease +9

Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis

Ludwig Kappos · The Lancet · 1998 · 941 citations · Full text

Placebo-controlled Multicentre, Autoimmune Disease, Neurological Disorder +9

Interferon beta‐lb in the treatment of multiple sclerosis

Neurology · 1995 · 914 citations

Neurological Disorder, Immunology, Clinical Neurology +16